Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Circulating PCSK9 as a prognostic biomarker of cardiovascular events in individuals with type 2 diabetes: evidence from a 16.8-year follow-up study

Fig. 2

Levels of PCSK9 according to complications. Marginal means plot of serum PCSK9 in patients with type 2 diabetes mellitus  grouped according to presence of A diabetic nephropathy, B history of MACE and C statin therapy, sex and presence of complications. *p < 0.05; ***p < 0.001 for Tukey’s post-hoc tests following one-way ANCOVA. MACE major adverse cardiovascular events, PCSK9 proprotein convertase subtilisin/kexin type 9

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840